S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
pixel
pixel
S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
pixel
pixel
S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
pixel
pixel
S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
pixel
pixel
Log in
NASDAQ:NERV

Minerva Neurosciences Stock Forecast, Price & News

$3.45
+0.74 (+27.31 %)
(As of 01/19/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.26
Now: $3.45
$3.75
50-Day Range
$2.26
MA: $2.67
$4.01
52-Week Range
$1.81
Now: $3.45
$15.22
Volume7.51 million shs
Average Volume1.42 million shs
Market Capitalization$147.23 million
P/E RatioN/A
Dividend YieldN/A
Beta1.49
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of schizophrenia. The company is also developing seltorexant that has completed Phase IIb clinical trial for treating insomnia and major depressive disorders; and MIN-301, which is in pre-clinical trial, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of the roluperidone worldwide, excluding Asia; and co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of seltorexant. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was founded in 2007 and is based in Waltham, Massachusetts.
Minerva Neurosciences logo

MarketRank

Overall MarketRank

1.55 out of 5 stars

Analyst Opinion: 3.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NERV
CUSIPN/A
Phone617-600-7373
Employees13

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.71 per share

Profitability

Net Income$-72,180,000.00

Miscellaneous

Market Cap$147.23 million
Next Earnings Date3/8/2021 (Estimated)
OptionableOptionable
$3.45
+0.74 (+27.31 %)
(As of 01/19/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NERV News and Ratings via Email

Sign-up to receive the latest news and ratings for NERV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Minerva Neurosciences (NASDAQ:NERV) Frequently Asked Questions

How has Minerva Neurosciences' stock price been impacted by COVID-19 (Coronavirus)?

Minerva Neurosciences' stock was trading at $6.36 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, NERV stock has decreased by 45.8% and is now trading at $3.45.
View which stocks have been most impacted by COVID-19
.

Is Minerva Neurosciences a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Minerva Neurosciences in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Minerva Neurosciences stock.
View analyst ratings for Minerva Neurosciences
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Minerva Neurosciences?

Wall Street analysts have given Minerva Neurosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Minerva Neurosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Minerva Neurosciences' next earnings date?

Minerva Neurosciences is scheduled to release its next quarterly earnings announcement on Monday, March 8th 2021.
View our earnings forecast for Minerva Neurosciences
.

How were Minerva Neurosciences' earnings last quarter?

Minerva Neurosciences, Inc. (NASDAQ:NERV) posted its quarterly earnings results on Monday, November, 2nd. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.22) by $0.03.
View Minerva Neurosciences' earnings history
.

What price target have analysts set for NERV?

5 brokers have issued 12-month price targets for Minerva Neurosciences' shares. Their forecasts range from $2.00 to $10.00. On average, they expect Minerva Neurosciences' stock price to reach $6.75 in the next year. This suggests a possible upside of 95.7% from the stock's current price.
View analysts' price targets for Minerva Neurosciences
or view Wall Street analyst' top-rated stocks.

Who are some of Minerva Neurosciences' key competitors?

What other stocks do shareholders of Minerva Neurosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Minerva Neurosciences investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), PTC Therapeutics (PTCT), Immunomedics (IMMU), VBI Vaccines (VBIV), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Moderna (MRNA), T2 Biosystems (TTOO) and Advanced Micro Devices (AMD).

Who are Minerva Neurosciences' key executives?

Minerva Neurosciences' management team includes the following people:
  • Dr. Rémy Luthringer, Exec. Chairman & CEO (Age 60, Pay $736.03k)
  • Mr. Geoffrey Robin Race, Exec. VP, CFO & Chief Bus. Officer (Age 60, Pay $516.84k)
  • Mr. Joseph Reilly, Sr. VP & COO (Age 46)
  • Mr. Frederick W. Ahlholm, Sr. VP & Chief Accounting Officer (Age 55)
  • Mr. William B. Boni, VP of Investor Relations & Corp. Communications (Age 69)
  • Mr. Devin Whittemore Smith, Sr. VP, Gen. Counsel & Sec. (Age 53)
  • Dr. Michael Davidson, Chief Medical Officer (Age 71)
  • Dr. Jay B. Saoud Ph.D., Sr. VP and Head of R&D (Age 62)

What is Minerva Neurosciences' stock symbol?

Minerva Neurosciences trades on the NASDAQ under the ticker symbol "NERV."

How do I buy shares of Minerva Neurosciences?

Shares of NERV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Minerva Neurosciences' stock price today?

One share of NERV stock can currently be purchased for approximately $3.45.

How big of a company is Minerva Neurosciences?

Minerva Neurosciences has a market capitalization of $147.23 million. The biopharmaceutical company earns $-72,180,000.00 in net income (profit) each year or ($1.85) on an earnings per share basis. Minerva Neurosciences employs 13 workers across the globe.

What is Minerva Neurosciences' official website?

The official website for Minerva Neurosciences is www.minervaneurosciences.com.

How can I contact Minerva Neurosciences?

Minerva Neurosciences' mailing address is 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-600-7373 or via email at [email protected]

This page was last updated on 1/19/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.